The purpose of a cancer vaccine is to initiate and focus the enormous power of the immune system on tumor cells. ImmuneFx does this in the most effective manner possible. In fact, ImmuneFx primes and educates the immune system to destroy tumor cells throughout the body without harming healthy cells and tissues. It does this by expressing a bacterial antigen on the surface of a patient’s own tumor cells.
Unlike other cancer vaccines, ImmuneFx combines cell AND gene therapy to promote cross-presentation and priming.
As a CELL THERAPY, ImmuneFx breaks tolerance to multiple tumor-associated antigens on many different heterologous tumor cells. It does this by a phenomenon known as inter-antigenic epitope spreading. In doing this, it maximizes immunity to weakly immunogenic altered self-antigens and increases the inclusion of the most potent immune rejection target antigens. This, in turn, decreases the escape of antigen-loss variants.
As a GENE THERAPY, ImmuneFx increases immune targeting to phenotypic variability between lesions in diseases such as melanoma where the variability between lesions is quite extensive even within individual patients. As a gene therapy, ImmuneFx also capitalizes on the broad specificity of pattern recognition receptors such as toll-like receptors by expressing the bacterial antigen on the surface of the tumor cells where it is recognized by the toll-like receptors as a ‘danger structural motif’. Further, since the expressed protein is processed in much the same way that a viral antigen is processed in the cytoplasm and displayed on the tumor cell surface, a more comprehensive immune response to this danger signal is favored.
ImmuneFx technology is simple yet powerful. Like a single red flag placed at the top of a snow-covered mountain that sets in motion the breathtaking power of an avalanche, a single bacterial gene is taken up by a tumor cell, is expressed on the surface of that tumor cell acting like a red flag to the immune system. Easily and simply, the fearsome power of the immune response is unleashed against every tumor-specific antigen present on that and other tumor cells throughout the body. Simple yet powerful.
The power of ImmuneFx has been demonstrated through the > 1,200 doses administered so far to patients with naturally occurring cancers. While the patients to date have been of the 4-legged variety, the results are that more data have been collected prior to entering human trials than for any other cancer vaccine tested in clinical trials so far. The truth is that data accrued with companion animals with naturally occurring cancers, some 83 breeds in 4 species with close to 30 different types of cancer, have much more predictive value on what will happen when administered to humans than any experimentally induced laboratory mouse model ever could. With zero side-effects and a strong correlation between clinical efficacy and immune response, ImmuneFx has proven its ability to prime and present the complete repertoire of tumor antigens to the immune system in such a way that evokes a broad spectrum of immune response including innate and adaptive immunity, i.e. Th cells, cytotoxic T cells, B cells and memory cells.
ImmuneFx, a true multi-indication cancer vaccine, that effectively combines cell and gene therapy to mobilize multiple components of the innate and adaptive immune systems that target the entire antigenic repertoire of heterologous tumors by maximizing antigen presentation and inter-antigenic epitope spreading in a clinically relevant manner.
Whether delivered as cost-effective direct DNA or a logistically seamless autologous vaccine, ImmuneFx is personalized to that particular patient. As a DNA vaccine, ImmuneFx is an off-the-shelf multi-indication product that is easy and cost-effective to produce and is delivered by intratumoral injection. As an autologous vaccine, ImmuneFx can be turned around in days from biopsy to administration. This form of the vaccine is irradiated and cryogenically stored until it is administered through a simple intradermal injection.
The fact that ImmuneFx is perhaps the best method yet developed for priming a clinically relevant immune response to multiple tumor-associated antigens, is especially important when considering vaccine combinations with checkpoint inhibitors. This is because checkpoint inhibitors require a substantial pool of activated T cells that are often times inactive in the tumor microenvironment and may not even exist if the tumor is weakly immunogenic. Therefore, the induction of new tumor antigen-specific cytotoxic T cells is of critical importance to maximize the effects of these immune modulators.